Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654875 | 0.90 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL3819428 | 0.88 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL3810093 | 0.85 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL3810106 | 0.85 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL4623773 | 0.85 | TRPV1 (0.70) | TRPV1 | |
| SCHEMBL4653641 | 0.84 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL3813818 | 0.83 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL4653812 | 0.83 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL3815572 | 0.80 | EPHX2 (0.67) | TRPV1 | |
| SCHEMBL4622881 | 0.80 | TRPV1 (0.56) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303483-B1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2008-04-23 | — | — | EP | claimed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | claimed |
| US-20070249720-A1 | Thiourea Derivative-Containing Pharmaceutical Composition Having Improved Solubility and Bioavailability | AMOREPACIFIC CORPORATION (KR) | 2007-10-25 | — | — | US | claimed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | claimed |
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| EP-1303483-B1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2008-04-23 | — | — | EP | disclosed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | disclosed |
| US-20070249720-A1 | Thiourea Derivative-Containing Pharmaceutical Composition Having Improved Solubility and Bioavailability | AMOREPACIFIC CORPORATION (KR) | 2007-10-25 | — | — | US | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | TRPV1 18/4885 |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TAS2R5 | TRPV1 1/4885 |
| US-20070249720-A1 | Thiourea Derivative-Containing Pharmaceutical Composition Having Improved Solubility and Bioavailability | TPMT, ABCG2, TBCD | TRPV1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.